渤健Biogen (BIIB) 2013年年度报告「NASDAQ」.pdf

《渤健Biogen (BIIB) 2013年年度报告「NASDAQ」.pdf》由会员分享，可在线阅读，更多相关《渤健Biogen (BIIB) 2013年年度报告「NASDAQ」.pdf（28页珍藏版）》请在三个皮匠报告上搜索。

1、2013 ANNUAL REPORT|BIOGENIDEC.COM/AR2013“My passion is my life and my quality of life day in,day out.”Kate Ouellette,volunteer,small business owner,mother and wife4|BIOGENIDEC.COM/AR2013Revenues$in millions09 10111213$4,377$5,049$5,516$6,932$4,716Non-GAAP Diluted EPS*$4.12$5.90$6.53$8.96$5.1509 1011

2、1213Free Cash Flow*$in millions$909$1,452$1,625$2,099$1,52009 10111213FINANCIAL HIGHLIGHTS*Non-GAAP diluted Earnings Per Share(EPS)and free cash flow are non-GAAP financial measures.A reconciliation of GAAP to non-GAAP diluted EPS and free cash flow amounts are set forth on pages 20 and 21 of this a

3、nnual report.1|BIOGENIDEC.COM/AR2013“Biogen Idec is in the business of understanding patient needs and the biology of disease.We are in the business of transforming the lives of the patients we serve.Ultimately,our success will be measured by the impact we have on peoples lives and the quality of li

4、fe associated with that change.”George A.Scangos,Ph.D.Chief Executive Officer2|BIOGENIDEC.COM/AR20132013 was an excellent year for Biogen Idec and the patients we serve,marked by important commercial and clinical progress as we brought important new therapies to market,advanced the next generation o

5、f potential treatments through the pipeline and prepared for critical readouts on investigational compounds that we expect to shape our future.A year ago I wrote to you that our company is fully aligned behind a crisply defined mission and business strategy.Today,I can say that we are increasingly c

6、onfident in our approach,and remain deeply committed to robust investment in the science that is our heritage and will be our future.And once again,we achieved strong financial results.Revenue for 2013 was$6.9 billion,an increase of 26%from 2012,and we enjoyed double-digit growth in both earnings pe